---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-25-001500"
form_type: "8-K/A"
ticker: "PTHS"
cik: "0001919246"
company_name: "Pelthos Therapeutics Inc."
filed_at: "2025-09-16T23:59:59+00:00"
generated_at: "2026-05-17T06:33:25.653243+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pelthos (PTHS) files LNHC unaudited financials and pro forma data post-merger closed July 1, 2025

## Summary
- Merger closed July 1, 2025; issued ~31,278 Series A Preferred shares to Ligand; PIPE raised ~$50.1M gross.
- LNHC unaudited balance sheets as of June 30, 2025 and 2024; pro forma financial info provided for combined entity.
- ZELSUVMI (berdazimer gel) FDA approved Jan 2024 for molluscum contagiosum; 13% royalty to Ligand on worldwide sales.
- Nomis RoyaltyVest receives 1.5% royalty on ZELSUVMI net sales; additional royalty agreements with Ligand and Madison.
- Company holds exclusive license from Ligand for ZELSUVMI ex-Japan; 19,265 sq ft facility in Durham, NC.

## SEC filing metadata
- accession: 0001753926-25-001500
- form_type: 8-K/A
- ticker: PTHS
- cik: 0001919246
- company_name: Pelthos Therapeutics Inc.
- filed_at: 2025-09-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01, 2.01, 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1919246/000175392625001500/0001753926-25-001500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1919246/000175392625001500/g084946_8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-25-001500
- JSON: https://secwatch.observer/filing/0001753926-25-001500.json
- Plain text: https://secwatch.observer/filing/0001753926-25-001500.txt

## Key facts
- M&A Transactions
  Pelthos Therapeutics Inc. completed an acquisition involving LNHC, Inc. and Ligand Pharmaceuticals Incorporated (closed 2025-07-01).
  - Action: acquisition
  - Counterparty: LNHC, Inc. and Ligand Pharmaceuticals Incorporated
  - Closing: 2025-07-01
  source text: On July 1, 2025, Channel Therapeutics Corporation, Merger Sub, LNHC, and solely for the purposes of Article III thereof, Ligand consummated the Merger
  evidence_url: https://www.sec.gov/Archives/edgar/data/1919246/000175392625001500/0001753926-25-001500-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.